After attending this symposium, learners will be able to:
Discuss the mechanism of action of ileal bile acid transporter (IBAT) inhibitors and their proposed effects on cholestatic liver disease and metabolic disease.
Describe the pathophysiological features of cholestatic liver diseases, as well as clinical outcomes associated with these conditions.
Describe the pathophysiological features of metabolic liver diseases, as well as clinical outcomes associated with these conditions.
Recall clinical trial data regarding the efficacy and safety of IBAT inhibitors in the treatment of cholestatic liver disease, including biliary atresia and progressive familial intrahepatic cholestasis (PFIC).
Presented for attendees of The Liver Meeting Digital Experience™. This event is sponsored by Liberum IME and supported by Albireo Pharmaceuticals. This is not an official event of the American Association for the Study of Liver Diseases.